Desipramine pharmacokinetics in Chinese and Caucasian volunteers.

Mv, Rudorfer; Ea, Lane; Chang, Wen Ho; Zhang, Bo; Wz, Potter

doi:10.1111/j.1365-2125.1984.tb02368.x

Cited by 67 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such drugs include diphenhydramine (Spector et al, 1980), desipramine (Rudorfer et al, 1984) and nortriptyline (Kishimoto & Hollister, 1984 (Kalow et al, 1979) and of caffeine (Grant et al, 1983), as assessed by urine metabolite concentrations.…”

Section: Introductionmentioning

confidence: 99%

Genetic polymorphism of mephenytoin p(4′)‐hydroxylation: difference between Orientals and Caucasians.

Jurima¹,

Inaba²,

Kadar³

et al. 1985

Brit J Clinical Pharma

105

View full text Add to dashboard Cite

The genetically controlled mephenytoin p(4′)‐hydroxylation capacity was determined in 118 Caucasians and 70 Orientals. After an oral dose of 50 or 100 mg of racemic mephenytoin, the amount of p(4′)‐ hydroxymephenytoin in 24 h urine was measured by gas chromatography. Bimodal distribution was found with 9/70 (13%) Orientals and 5/118 (4%) Caucasians demonstrating deficient p(4′)‐hydroxylation. The statistically significant difference between Orientals and Caucasians (P less than 0.05) was accounted for by the high incidence of poor metabolizers among the Japanese subjects, 7/31 (23%). The frequency among Chinese subjects, 2/39 (5%), was similar to the frequency among Caucasians.

show abstract

Section: Introductionmentioning

confidence: 99%

Genetic polymorphism of mephenytoin p(4′)‐hydroxylation: difference between Orientals and Caucasians.

Jurima¹,

Inaba²,

Kadar³

et al. 1985

Brit J Clinical Pharma

105

View full text Add to dashboard Cite

show abstract

“…Some reported that plasma clomipramine concentrations and drug-related adverse effects were significantly higher among Asians (Pakistani and Indian) compared with white British investigators [49,50]. Others reported that the mean plasma clearance of desipramine was significantly higher among whites than the Chinese even after correcting for body weight [51]. There was no significant difference in half-life or plasma protein binding between the two groups.…”

Section: Pharmacogenetics Of Antidepressantsmentioning

confidence: 80%

Pharmacogenetics of bipolar disorder

Mansour¹,

Alda²,

Nimgaonkar³

2002

Curr Psychiatry Rep

View full text Add to dashboard Cite

To review the pharmacogenetics of bipolar disorders, the authors searched databases for genetic association and linkage studies involving response to long-term prophylactic lithium treatment, as well as treatment with antidepressants or clozapine. Significant ethnic variations in the metabolism and efficacy of antidepressants, as well as clozapine, have been reported by several groups. Systematic studies suggest that that genetic factors affect the response to prophylactic lithium treatment. Numerous associations between the three traits of interest and candidate gene polymorphisms have been proposed. Among these, an association between the serotonin transporter gene and response to serotonin reuptake inhibitors appears robust. Considerable interest has also focused on serotonergic gene polymorphisms and response to clozapine. Response to pharmacotherapy in bipolar disorders may be mediated by genetic factors, but the role played by heritability is unknown.

show abstract

“…These kinds of studies could reveal information regarding differences among ethnic groups, relevant to optimal dosing strategies. For example, a number of studies have compared clearance rates and peak plasma concentrations for Asian versus White subjects, with mixed findings (Kishimoto and Hollister 1984;Rudorfer et al 1984;Rudorfer et al 1985). Even less is known about pharmacokinetic response in other minority groups (Sramek and Pi 1996).…”

Section: S Department Of Health and Human Services 2001; Freedenthanmentioning

confidence: 97%

Treatment of Culturally Diverse Children and Adolescents with Depression

Stewart

Simmons²,

Habibpour

2012

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

This article is written for the practitioners treating depression in ethnic minority youth. It will review the context in which services are delivered to these youth: Researchers have recognized persistent ethnic differences in terms of utilization of services and unmet need. Furthermore, when ethnic minority youth do receive pediatric mental health care, the services that they receive may differ from those given to White patients. The reasons for these discrepancies have been examined in numerous studies, and have included contextual variables (economics, availability, and accessibility of services), patient variables (differences in prevalence or manifestation of the disorder, cultural beliefs and attitudes, preferential use of alternative or informal services, health literacy, and adherence), and provider variables (referral bias and patient-provider communication). Information about the differences between White and minority youth in the pharmacodynamics and pharmacokinetics of the antidepressant response is still limited. There are significant challenges for developing evidence-based guidelines that inform practice with these youth, hinging on both the underrepresentation of ethnic minority groups in clinical trials, and the great variability in biological and cultural characteristics of individuals in ethnic minority categories. Awareness on the part of the practitioner of the cultural variables that influence help-seeking and ongoing utilization of mental health services may aid in the engagement, effective treatment, and retention of ethnic minority children and adolescents with depression. However, given the great heterogeneity that exists within any cultural grouping, clinicians will need to integrate information about cultural patterns with that obtained from the individual patient and family to inform optimal practices for each patient. This article is written to enhance awareness on the part of the practitioner as to the variables that influence psychiatric care for depression in culturally diverse youth. The mental health needs of minority youth are not well served: They are treated less frequently, and when they are treated, the services they receive are less frequently adequate. The reasons that have been proposed for the disparities in their care, particularly with regard to diagnosis and treatment for depression, will be reviewed. They include contextual factors (such as economics, insurance, and other variables affecting the availability of services) patient and family factors (such as prevalence, symptom presentation, and values and beliefs that influence whether patients are referred to and avail themselves of services), and provider factors (such as referral bias and patient-provider communication, which affect whether patients engage and stay in treatment). The implications for the practitioner treating ethnic minority youth with depression will be discussed. Culture, as used in this article, refers to the common values, beliefs, and social behaviors of individuals with a shared heritage. S...

show abstract

Desipramine pharmacokinetics in Chinese and Caucasian volunteers.

Cited by 67 publications

References 29 publications

Genetic polymorphism of mephenytoin p(4′)‐hydroxylation: difference between Orientals and Caucasians.

Genetic polymorphism of mephenytoin p(4′)‐hydroxylation: difference between Orientals and Caucasians.

Pharmacogenetics of bipolar disorder

Treatment of Culturally Diverse Children and Adolescents with Depression

Contact Info

Product

Resources

About